{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:30:33Z","timestamp":1761060633404},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.hfc.2018.06.002","type":"journal-article","created":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T05:18:53Z","timestamp":1534569533000},"page":"525-535","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Aldosterone Receptor Blockade in Heart Failure with Preserved Ejection Fraction"],"prefix":"10.1016","volume":"14","author":[{"given":"Ajith","family":"Nair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Deswal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.hfc.2018.06.002_bib1","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics\u20132017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.hfc.2018.06.002_bib2","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2018.06.002_bib3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.289.2.194","article-title":"Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic","volume":"289","author":"Redfield","year":"2003","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.hfc.2018.06.002_bib4","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1001\/jama.296.18.2209","article-title":"Systolic and diastolic heart failure in the community","volume":"296","author":"Bursi","year":"2006","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.hfc.2018.06.002_bib5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s11886-005-0074-7","article-title":"Diastolic dysfunction and diastolic heart failure: mechanisms and epidemiology","volume":"7","author":"Deswal","year":"2005","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"10.1016\/j.hfc.2018.06.002_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjcard.2009.09.041","article-title":"Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus","volume":"105","author":"Aguilar","year":"2010","journal-title":"Am J Cardiol"},{"issue":"17","key":"10.1016\/j.hfc.2018.06.002_bib7","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.jacc.2017.09.006","article-title":"Biological phenotypes of heart failure with preserved ejection fraction","volume":"70","author":"Lewis","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.hfc.2018.06.002_bib8","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/CIRCRESAHA.108.193326","article-title":"Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium","volume":"104","author":"Borbely","year":"2009","journal-title":"Circ Res"},{"issue":"16","key":"10.1016\/j.hfc.2018.06.002_bib9","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1161\/CIRCULATIONAHA.105.587519","article-title":"Myocardial structure and function differ in systolic and diastolic heart failure","volume":"113","author":"van Heerebeek","year":"2006","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.hfc.2018.06.002_bib10","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1161\/CIRCULATIONAHA.114.013215","article-title":"Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin","volume":"131","author":"Zile","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2018.06.002_bib11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fphys.2015.00078","article-title":"Abnormal calcium homeostasis in heart failure with preserved ejection fraction is related to both reduced contractile function and incomplete relaxation: an electromechanically detailed biophysical modeling study","volume":"6","author":"Adeniran","year":"2015","journal-title":"Front Physiol"},{"issue":"4","key":"10.1016\/j.hfc.2018.06.002_bib12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A\u00a0novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2018.06.002_bib13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1161\/CIRCHEARTFAILURE.113.000887","article-title":"Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial","volume":"7","author":"Shah","year":"2014","journal-title":"Circ Heart Fail"},{"issue":"5","key":"10.1016\/j.hfc.2018.06.002_bib14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.114.001583","article-title":"Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial","volume":"7","author":"Shah","year":"2014","journal-title":"Circ Heart Fail"},{"issue":"5","key":"10.1016\/j.hfc.2018.06.002_bib15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1161\/CIRCULATIONAHA.115.015884","article-title":"Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"132","author":"Shah","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2018.06.002_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1001\/jamacardio.2015.0356","article-title":"Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist","volume":"1","author":"Pfeffer","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.hfc.2018.06.002_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejheart.2004.04.013","article-title":"The clinical implications of aldosterone escape in congestive heart failure","volume":"6","author":"Struthers","year":"2004","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.hfc.2018.06.002_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","article-title":"Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism","volume":"25","author":"Brilla","year":"1993","journal-title":"J\u00a0Mol Cell Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2018.06.002_bib19","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/01.CIR.63.3.645","article-title":"Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure","volume":"63","author":"Dzau","year":"1981","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hfc.2018.06.002_bib20","doi-asserted-by":"crossref","first-page":"3a","DOI":"10.1016\/0002-9149(93)90238-8","article-title":"Aldosterone and antialdosterone therapy in congestive heart failure","volume":"71","author":"Weber","year":"1993","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.hfc.2018.06.002_bib21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.hfc.2018.06.002_bib22","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hfc.2018.06.002_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hfc.2018.06.002_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1253\/circj.CJ-11-1424","article-title":"Contemporary medical management of systolic heart failure","volume":"76","author":"Nair","year":"2012","journal-title":"Circ J"},{"issue":"19","key":"10.1016\/j.hfc.2018.06.002_bib25","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"issue":"9386","key":"10.1016\/j.hfc.2018.06.002_bib26","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of Candesartan in Patients with Chronic Heart Failure and Preserved Left-Ventricular Ejection Fraction: the CHARM-preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.hfc.2018.06.002_bib27","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.hfc.2018.06.002_bib28","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). RALES investigators","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.hfc.2018.06.002_bib29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","article-title":"Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure","volume":"110","author":"Mottram","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hfc.2018.06.002_bib30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ejhf.203","article-title":"Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial","volume":"17","author":"Edelmann","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10.1016\/j.hfc.2018.06.002_bib31","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.hfc.2018.06.002_bib32","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF)","volume":"17","author":"Deswal","year":"2011","journal-title":"J\u00a0Card Fail"},{"issue":"18","key":"10.1016\/j.hfc.2018.06.002_bib33","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2009.08.021","article-title":"Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone","volume":"54","author":"Mak","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.hfc.2018.06.002_bib34","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.cardfail.2014.05.010","article-title":"Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction","volume":"20","author":"Kurrelmeyer","year":"2014","journal-title":"J\u00a0Card Fail"},{"issue":"10","key":"10.1016\/j.hfc.2018.06.002_bib35","doi-asserted-by":"crossref","first-page":"e002137","DOI":"10.1161\/JAHA.115.002137","article-title":"Effect of mineralocorticoid receptor antagonists on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction: a meta-analysis and systematic review","volume":"4","author":"Pandey","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"17","key":"10.1016\/j.hfc.2018.06.002_bib36","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2016.07.763","article-title":"Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction","volume":"68","author":"Kosmala","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.hfc.2018.06.002_bib37","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hfc.2018.06.002_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.hfc.2018.06.002_bib39","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.jacc.2012.04.064","article-title":"What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?","volume":"60","author":"Campbell","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.hfc.2018.06.002_bib40","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT - new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.hfc.2018.06.002_bib41","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMe1401231","article-title":"Lessons from the TOPCAT trial","volume":"370","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hfc.2018.06.002_bib42","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jacc.2011.03.057","article-title":"Influence of global region on outcomes in heart failure beta-blocker trials","volume":"58","author":"O'Connor","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2018.06.002_bib43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ahj.2012.06.006","article-title":"Implications of geographical variation on clinical outcomes of cardiovascular trials","volume":"164","author":"Mentz","year":"2012","journal-title":"Am Heart J"},{"issue":"20","key":"10.1016\/j.hfc.2018.06.002_bib44","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.jacc.2008.07.056","article-title":"Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program","volume":"52","author":"Blair","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.hfc.2018.06.002_bib45","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jacc.2012.12.044","article-title":"B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction","volume":"61","author":"van Veldhuisen","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2018.06.002_bib46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijcard.2017.01.130","article-title":"BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: the atherosclerosis risk in communities surveillance study","volume":"233","author":"Khalid","year":"2017","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2018.06.002_bib47","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jchf.2016.11.015","article-title":"Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial","volume":"5","author":"Anand","year":"2017","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.hfc.2018.06.002_bib48","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12872-016-0425-x","article-title":"Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis","volume":"16","author":"Berbenetz","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"10.1016\/j.hfc.2018.06.002_bib49","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.hfc.2018.06.002_bib50","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","article-title":"Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure)","volume":"53","author":"van Veldhuisen","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.hfc.2018.06.002_bib51","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.hfc.2018.06.002_bib52","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","article-title":"Phenomapping for novel classification of heart failure with preserved ejection fraction","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.hfc.2018.06.002_bib53","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jcmg.2011.08.014","article-title":"A\u00a0randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome","volume":"4","author":"Kosmala","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.hfc.2018.06.002_bib54","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1161\/CIRCHEARTFAILURE.115.002249","article-title":"Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"8","author":"Shah","year":"2015","journal-title":"Circ Heart Fail"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713618300527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713618300527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T18:50:58Z","timestamp":1661799058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713618300527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1551713618300527"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2018.06.002","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aldosterone Receptor Blockade in Heart Failure with Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2018.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}